In last trading session, Arbutus Biopharma Corporation (NASDAQ:ABUS) saw 2.42 million shares changing hands with its beta currently measuring 2.67. Company’s recent per share price level of $3.22 trading at -$0.08 or -2.42% at ring of the bell on the day assigns it a market valuation of $443.07M. That closing price of ABUS’s stock is at a discount of -101.86% from its 52-week high price of $6.50 and is indicating a premium of 24.53% from its 52-week low price of $2.43. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.64 million shares which gives us an average trading volume of 9.58 million if we extend that period to 3-months.
For Arbutus Biopharma Corporation (ABUS), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.40. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.2 in the current quarter.
Arbutus Biopharma Corporation (NASDAQ:ABUS) trade information
Upright in the red during last session for losing -2.42%, in the last five days ABUS remained trading in the red while hitting it’s week-highest on Friday, 01/07/22 when the stock touched $3.22 price level, adding 11.05% to its value on the day. Arbutus Biopharma Corporation’s shares saw a change of -17.22% in year-to-date performance and have moved -9.55% in past 5-day. Arbutus Biopharma Corporation (NASDAQ:ABUS) showed a performance of -22.22% in past 30-days. Number of shares sold short was 8.06 million shares which calculate 0.35 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $6.30 to the stock, which implies a rise of 48.89% to its current value. Analysts have been projecting $4.00 as a low price target for the stock while placing it at a high target of $10.00. It follows that stock’s current price would drop -210.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -24.22% for stock’s current value.
Arbutus Biopharma Corporation (ABUS) estimates and forecasts
Statistics highlight that Arbutus Biopharma Corporation is scoring comparatively higher than the scores of other players of the relevant industry. The company added 21.05% of value to its shares in past 6 months, showing an annual growth rate of 14.00% while that of industry is 7.90. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 13.00% in the current quarter and calculating 9.50% increase in the next quarter. This year revenue growth is estimated to rise 54.30% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.87 million for the same. And 3 analysts are in estimates of company making revenue of $3.3 million in the next quarter that will end on Mar 2022. Company posted $2.39 million and $3.31 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 20.30% while estimating it to be -0.30% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 6.20% during past 5 years.
Arbutus Biopharma Corporation is more likely to be releasing its next quarterly report between November 01 and November 05 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Arbutus Biopharma Corporation (NASDAQ:ABUS)’s Major holders
Insiders are in possession of 30.77% of company’s total shares while institution are holding 26.47 percent of that, with stock having share float percentage of 38.24%. Investors also watch the number of corporate investors in a company very closely, which is 26.47% institutions for Arbutus Biopharma Corporation that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at ABUS for having 5.94 million shares of worth $25.46 million. And as of Sep 29, 2021, it was holding 4.39% of the company’s outstanding shares.
The second largest institutional holder is RTW Investments LP, which was holding about 4.73 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 3.50% of outstanding shares, having a total worth of $20.31 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 29, 2021, the former fund manager was holding 2.33 million shares of worth $9.99 million or 1.72% of the total outstanding shares. The later fund manager was in possession of 1.86 million shares on Oct 30, 2021, making its stake of worth around $7.5 million in the company or a holder of 1.38% of company’s stock.